Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease

Journal of Clinical Investigation

Volumn 112, Issue 3, 2003, Pages 415-422

  Monsonego, Alon ^a   Zota, Victor ^a   Karni, Arnon ^a   Krieger, Jeffery I ^a   Bar Or, Amit ^a   Bitan, Gal ^a   Budson, Andrew E ^a   Sperling, Reisa ^a   Selkoe, Dennis J ^a   Weiner, Howard L ^a  

^a Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; EPITOPE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); AUTOANTIGEN; CYTOKINE; PEPTIDE FRAGMENT;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DESIGN; HUMAN; HUMAN CELL; MEMORY; MENINGOENCEPHALITIS; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; AMINO ACID SUBSTITUTION; ANIMAL; BINDING SITE; CASE CONTROL STUDY; EPITOPE MAPPING; FEMALE; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMINO ACID SUBSTITUTION; AMYLOID BETA-PROTEIN; ANIMALS; AUTOANTIGENS; BINDING SITES; CASE-CONTROL STUDIES; CYTOKINES; EPITOPE MAPPING; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 0041886776     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200318104     Document Type: Article

References (55)

1. Price, D.L., and Sisodia, S.S. 1998. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21:479-505.
2. Selkoe, D.J. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741-766.
3. Urbanc, B., et al. 2002. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 99:13990-13995.
4. Jarrett, J.T., and Lansbury, P.T., Jr. 1993. Seeding " one-dimensional crystallization" of amyloid a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 73:1055-1058.
5. McGeer, E.G., and McGeer, P.L. 1998. The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol 33:371-378.
6. Cooper, N.R., Kalaria, R.N., McGeer, P.L., and Rogers, J. 2000. Key issues in Alzheimer's disease inflammation. Neurobiol. Aging, 21:451-453.
7. Akiyama, H., et al. 2000, Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:383-421.
8. Togo, T., et al. 2002. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J. Neuroimmunol. 124:83-92.
9. Lue, L.F., et al. 2001. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia. 35:72-79.
10. Haas, J., Storch-Hagenlocher, B., Biessmann, A., and Wildemann, B. 2002. Inducible nitric oxide synthase and argininosuccinate synthetase: coinduction in brain tissue of patients with Alzheimer's dementia and following stimulation with β-amyloid 1-42 in vitro. Neurosci. Lett. 322:21-125.
11. Heneka, M.T., et al. 2002. Noradrenergic depletion potentiates β-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 22:2434-2442.
12. Smits, H.A., et al. 2002. Amyloid-β-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol. 127:160-168.
13. Wyss-Coray, T., et al. 2003. Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nat. Med. 9:453-457.
14. Schenk, D., et al. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:173-177.
15. Morgan, D., et al. 2000. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:982-985.
16. Janus, C., et al. 2000. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:979-982,
17. Weiner, H.L., et al. 2000. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48:567-579.
18. Lemere, C.A., et al. 2000. Nasal A β treatment induces anti-A β antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. N. Y. Acad. Sci. 920:328-331.
19. Bard, F., et al. 2000. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-919.
20. Dodart, J.C., et al. 2002. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5:452-457.
21. Schenk, D. 2003. Immunization against Alzheimer's disease and other neurodegenerative disorders. D. Selkoe and Y. Christen, editors. Springer-Verlag New York Inc. New York, New York, USA. 130 pp.
22. Hock, C., et al. 2002. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8:1270-1275.
23. Pfeifer, M., et at. 2002. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science. 298:1379.
24. Nicoll, J.A., et al. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9:448-452.
25. Gammon, G., and Sercarz, E. 1989. How some T cells escape tolerance induction. Nature. 342:183-185.
26. Peterson, D.A., DiPaolo, R.J., Kanagawa, O., and Unanue, E.R. 1999. Quantitative analysis of the T cell repertoire that escapes negative selection. Immunity. 11:453-462.
27. Janeway, C.A., Jr. 1999. T cell development: a role for self-peptides in positive selection. Curr. Biol. 9:R342-R345.
28. Cohen, I.R. 1992. The cognitive principle challenges clonal selection. Inmunol. Today. 13:441-444.
29. Schwartz, M., and Cohen, I.R. 2000. Autoimmunity can benefit self-maintenance. Immunol. Today, 21:265-268.
30. Kitani, A., Chua, K., Nakamura, K., and Strober, W. 2000. Activated self-MHC-reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. J. Immunol. 165:691-702.
31. Cohen, I.R. 2001. Antigenic mimicry, clonal selection and autoimmunity. J. Autoimmun. 16:337-340.
32. Apostolou, I., Sarukhan, A., Klein, L., and von Boehmer, H. 2002. Origin of regulatory T cells with known specificity for antigen. Nat. Immunol. 3:756-763,
33. + regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by endogenous TCR expression. J. Immunol. 168:4399-4405.
34. Wekerle, H. 1993. T cell autoimmunity in the central nervous system. Intervirology. 35:95-100.
35. Becher, B., Prat, A., and Antel, J.P. 2000. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia. 29:293-304.
36. Hickey, W.F. 2001. Basic principles of immunological surveillance of the normal central nervous system. Glia. 36:118-124.
37. Gaskin, F., Finley, J., Fang, Q., Xu, S., and Fu, S.M. 1993. Human antibodies reactive with β-amyloid protein in Alzheimer's disease. J. Exp. Med. 177:1181-1186,
38. Lomakin, A., Benedek, G.B., and Teplow, D.B. 1999. Monitoring protein assembly using quasielastic light scattering spectroscopy. Methods Enzymol. 309:429-459.
39. McKhann, G., et al. 1984. Clinical diagnosis of Alzheimer's disease: report of the NlNCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:939-944.
40. Folstein, M.F., Folstein, S.E., and McHugh, P.R. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:189-198.
41. Fukaura, H., et al. 1996. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-β1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest 98:70-77.
42. Linton, P.J., Haynes, L., Klinman, N.R., and Swain, S.L. 1996. Antigen-independent changes in naive CD4 T cells with aging. J. Exp. Med. 184:1891-1900.
43. Bansal-Pakala, P., and Crof, M. 2002. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J. Immunol. 169:5005-5009,
44. Grubeck-Loebenstein, B., and Wick, G. 2002. The aging of the immune system. Adv. Immunol. 80:243-284,
45. Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R., and Sela, M. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1:242-248.
46. Duda, PW., Krieger, J.I., Schmied, M.C., Balentine, C., and Haner, D.A. 2000. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatirarner acetate. J. Immunol. 165:7300-7307.
47. Trieb, K., Ransmayr, G., Sgonc, R., Lassmann, H., and Grubeck-Loebenstein, B. 1996. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol. Aging. 17:541-547.
48. Cohen, I.R., and Schwartz, M. 1999. Autoimmune maintenance and neuroprotection of the central nervous system. J. Neuroimmunol. 100:111-114.
49. Weiner, H.L. 2001. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-β-secreting regulatory cells. Microbes Infect. 3:947-954.
50. Scheinecker, C., McHugh, R., Shevach, E.M., and Germain, R.N. 2002. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J. Exp. Med. 196:1079-1690.
51. Monsonego, A., Maron, R, Zota, V., Selkoe, D.J., and Weiner, H.L. 2001 Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98:10273-10278.
52. Furlan, R., et al. 2003. Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain. 126:285-291.
53. Mor, F., Quintana, F., Mimran, A., and Cohen, I.R. 2003. Autoimmune encephalomyelitis and uveitis induced by T cell immunity to selfβ -synuclein. J. Immunol. 170:628-634.
54. Wyss-Coray, T., et al. 2001. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat. Med. 7:612-618.
55. Hock, C., et al. 2003. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 38:S47-554.